Archives
RCT: Oral contezolid vs. linezolid in adults with complicated skin and soft tissue infections.
18 Mar, 2022 | 07:54h | UTCA Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections – Journal of Antimicrobial Therapy (link to abstract – $ for full-text)
Commentary on Twitter
Phase III efficacy & safety of oral contezolid Vs linezolid in adults with c.SSTIs
📌Non inferior
📌Interestingly:Contezolid demonstrated significant lower incidence thrombocytopenia (0% Wow vs 2.3%) & leucopenia (0.3% vs 3.4%) than linezolid
📌QIDP https://t.co/wSvxUInnkZ— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) March 11, 2022
Follow-up data from 2 randomized trials: efficacy and safety of Upadacitinib in patients with moderate to severe atopic dermatitis.
18 Mar, 2022 | 07:48h | UTC
The identification and management of high blood pressure using exercise blood pressure: current evidence and practical guidance.
18 Mar, 2022 | 07:57h | UTC
Multi-disciplinary care planning of ovarian cancer in older patients.
18 Mar, 2022 | 07:55h | UTC
RCT: Bortezomib in newly diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
18 Mar, 2022 | 07:50h | UTCChildren’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A: Duration of postpartum magnesium sulphate for the prevention of eclampsia.
18 Mar, 2022 | 07:38h | UTC
Systematic Review: Behavioral approaches to recruitment and retention in clinical trials.
18 Mar, 2022 | 07:40h | UTCRelated:
Perspective: How Can We Keep Participants in Clinical Trials Involved
RCT: Short-term radiotherapy plus chemotherapy vs. long-term chemoradiotherapy in locally advanced rectal cancer.
18 Mar, 2022 | 07:39h | UTC
M-A: Comparative efficacy and safety of pharmacological interventions to prevent Mother-to-Child transmission of hepatitis B virus.
18 Mar, 2022 | 07:37h | UTC
State of the Art Review: Recent advances in the diagnosis and management of cluster headache.
17 Mar, 2022 | 09:21h | UTCRecent advances in the diagnosis and management of cluster headache – The BMJ
2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.
17 Mar, 2022 | 09:26h | UTCCommentaries:
ACC Issues Clinical Guidance on CV Consequences of COVID-19 – American College of Cardiology
ACC Releases Guidance on CV Issues With COVID-19 – TCTMD
Key Points: 2022 ACC Decision Pathway on Cardiovascular Sequelae of COVID-19
Related:
Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.
The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.
COVID-19 infections increase risk of heart conditions up to a year later, study finds.
Commentary on Twitter (thread – click for more)
Access the full ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-acute Sequelae of SARS-CoV-2 Infection, and Return to Play: https://t.co/ph75qZxfpT #JACC @JACCJournals #CardioTwitter (8/8) pic.twitter.com/mpYJic6gem
— American College of Cardiology (@ACCinTouch) March 16, 2022
Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.
17 Mar, 2022 | 09:12h | UTCEfficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine
Related: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Treatments for moderate to severe COVID-19: Cochrane evidence.
17 Mar, 2022 | 09:19h | UTCTreatments for moderate to severe COVID-19: Cochrane evidence – Evidently Cochrane
Effectiveness of the Sputnik V, AstraZeneca, and Sinopharm vaccines for the risk of infection and death due to COVID-19 in people older than 60 years in Argentina.
17 Mar, 2022 | 09:10h | UTCCommentary: Evaluating COVID-19 vaccines in the real world – The Lancet
Treatments for mild COVID-19: Cochrane evidence.
17 Mar, 2022 | 09:17h | UTCTreatments for mild COVID-19: Cochrane evidence – Cochrane Library
[News release – not published yet] Empagliflozin phase III EMPA-KIDNEY trial will stop early due to evidence of efficacy in people with chronic kidney disease.
17 Mar, 2022 | 09:07h | UTC
Commentary on Twitter
Details of the design & pt characteristics now published:
6609 people from 8 countries
(UK, Germany, Italy, USA, Canada, China, Malaysia, Japan)
Mean age 64 years
1/3 female
1/2 diabetes; 1/2 without
3/4 eGFR <45 mL/min/1.73 m2.
1/2 uACR <300 mg/g https://t.co/jOD8kyp3i4 pic.twitter.com/YYpGPJDnV9— Martin Landray (@MartinLandray) March 16, 2022
Malignant Hypertension: Current perspectives and challenges.
17 Mar, 2022 | 09:03h | UTC
EULAR recommendations regarding lifestyle behaviors and work participation to prevent progression of rheumatic and musculoskeletal diseases.
17 Mar, 2022 | 08:58h | UTC
Commentary on Twitter
🚨 New very patient-centered #EULAR recommendations regarding lifestyle modifications published🚨
Areas covered include:
🏃♀️ 🏊 🚴♂️ — Excercise
🥗 🥙 🍝 — Diet
⚖️ 😱 — Weight
🍻 🍷🥃 — Alcohol
🚬 🚭 — Smoking
👨💼 👷♀️ 🏢 🏗️ — Work https://t.co/7ZroM2j98I— Annals of the Rheumatic Diseases (@eular_ARD) March 10, 2022
Denmark proposes ban on selling cigarettes to people born after 2010.
17 Mar, 2022 | 09:04h | UTCDenmark proposes ban on selling cigarettes to people born after 2010 – euronews
Commentary on Twitter
Happy to see this bold move by #Denmark to ban the sale of cigarettes to people born after 2010, and that the majority of 🇩🇰 people support this #NoTobacco decision. @WHO looks forward to working together to create ‘tobacco-free generations’ from now on.https://t.co/6BF0OeakrI
— Tedros Adhanom Ghebreyesus (@DrTedros) March 16, 2022
Guideline: Fall prevention in hospitals and nursing homes.
17 Mar, 2022 | 08:55h | UTC
Open-Label, multicenter study of Flecainide Acetate oral inhalation solution for acute conversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm.
17 Mar, 2022 | 09:01h | UTC
Commentary on Twitter
Inhalation of flecainide simply converts many episodes of recent onset atrial fibrillation #AHAJournals #HeartMonthhttps://t.co/vNXx4fKy2u pic.twitter.com/UNGA9DX3qM
— CircEP (@CirculationEP) February 25, 2022
Position Paper: Multi-modality imaging assessment of native valvular regurgitation.
17 Mar, 2022 | 08:49h | UTC
Management of the secondary spontaneous pneumothorax: current guidance, controversies, and recent advances.
17 Mar, 2022 | 08:51h | UTC
Summary: German evidence-based guidelines on focal therapy in localized prostate cancer.
17 Mar, 2022 | 08:47h | UTC
Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
17 Mar, 2022 | 08:45h | UTC